Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gary I, Cohen"'
Autor:
Jeffrey A. Sosman, Gary I. Cohen, Lawrence E. Flaherty, Robert M. Conry, Alberto S. Pappo, Richard F. Kefford, Joanna M. Brell, Michael Smylie, Douglas S. Reintgen, John M. Kirkwood, William E. Carson, Sandra J. Lee, Sanjiv S. Agarwala, Shaker R. Dakhil, Terry L. Evans, Mark R. Albertini, Uma N. M. Rao, Wai-Ki Yip, Michael B. Atkins, Vernon K. Sondak, Ahmad A. Tarhini
Publikováno v:
Journal of Clinical Oncology. 35:885-892
Purpose To test the efficacy of 4 weeks of intravenous (IV) induction with high-dose interferon (IFN) as part of the Eastern Cooperative Oncology Group regimen compared with observation (OBS) in patients with surgically resected intermediate-risk mel
Autor:
Ahmad A. Tarhini, Kim Margolin, Fengmin Zhao, Marc S. Ernstoff, John M. Kirkwood, Lisa H. Butterfield, Michael B. Atkins, Gary I. Cohen, David H. Lawson, Theresa L. Whiteside, Sandra J. Lee
Publikováno v:
Journal of Clinical Oncology. 33:4066-4076
Purpose We conducted a double-blind, placebo-controlled trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) and peptide vaccination (PV) on relapse-free survival (RFS) and overall survival (OS) in patients with r
Autor:
Ahmad A. Tarhini, Fengmin Zhao, Sandra J. Lee, Theresa L. Whiteside, Gary I. Cohen, Lisa H. Butterfield, Michael B. Atkins, John M. Kirkwood, Kim Margolin, Richard L. White, David H. Lawson
Purpose: E4697 was a multicenter intergroup randomized placebo-controlled phase III trial of adjuvant GM-CSF and/or a multiepitope melanoma peptide vaccine for patients with completely resected, high-risk stage III/IV melanoma. Experimental Design: A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b247b54d34cf321e89eb4eb12062b537
https://europepmc.org/articles/PMC5581724/
https://europepmc.org/articles/PMC5581724/
Autor:
Kevin, Kalinsky, Sandra, Lee, Krista M, Rubin, Donald P, Lawrence, Anthony J, Iafrarte, Darell R, Borger, Kim A, Margolin, Mario M, Leitao, Ahmad A, Tarhini, Henry B, Koon, Andrew L, Pecora, Anthony J, Jaslowski, Gary I, Cohen, Timothy M, Kuzel, Christopher D, Lao, John M, Kirkwood
Publikováno v:
Cancer. 123(14)
KIT-directed tyrosine kinase inhibitors such as imatinib have demonstrated benefits in KIT-mutant (KIT+) mucosal, acral, vulvovaginal, and chronically sun-damaged (CSD) melanoma. Dasatinib has superior preclinical activity in comparison with other ty